Você procurou por: sunitinibbehandling (Dinamarquês - Inglês)

der er begrænset viden om fortsat sunitinibbehandling af patienter med fistler.
limited information is available on the continued use of sunitinib in patients with fistulae.

alle patienter, der er i sunitinibbehandling, bør observeres tæt for tegn og symptomer på hypotyreose.
all patients should be observed closely for signs and symptoms of hypothyroidism on sunitinib treatment.

der sås hypertyreose hos 4 (1,7%) patienter i sunitinibbehandling, men ikke hos patienter i capecitabinbehandling.
hyperthyroidism was reported in 4 (1.7%) sunitinib subjects and no capecitabine subjects.

i det ene studie sås hypotyreose hos 15 (13,6%) af patienterne i sunitinibbehandling og hos 3 (2,9%) af patienterne i standardbehandling.
in one study, hypothyroidism was reported in 15 (13.6%) subjects on sunitinib and 3 (2.9%) subjects on standard of care.

desuden bør patienter, der er i sunitinibbehandling, observeres tæt for tegn og symptomer på thyroideadysfunktion, og de patienter, som udvikler tegn og/eller symptomer herpå, bør have foretaget laboratorieundersøgelse af thyroideafunktionen.
in addition, patients should be observed closely for signs and symptoms of thyroid dysfunction during treatment, and patients who develop any signs and/or symptoms suggestive of thyroid dysfunction should have laboratory testing of thyroid function performed as clinically indicated.

hvis der opstår angioødem på grund af overfølsomhed, afbrydes sunitinibbehandlingen, og standardbehandling iværksættes.
if angioedema due to hypersensitivity occurs, sunitinib treatment should be interrupted and standard medical care provided.